Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:RDY
CUSIPN/A
Phone91-40-4900-2900
Debt
Debt-to-Equity Ratio0.20
Current Ratio1.64
Quick Ratio1.19
Price-To-Earnings
Trailing P/E Ratio35.15
Forward P/E Ratio26.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.20 billion
Price / Sales2.67
Cash Flow$2.1013 per share
Price / Cash16.88
Book Value$11.71 per share
Price / Book3.03
Profitability
EPS (Most Recent Fiscal Year)$1.01
Net Income$151 million
Net Margins9.41%
Return on Equity11.74%
Return on Assets6.52%
Miscellaneous
Employees23,524
Outstanding Shares165,830,000
Market Cap$5.85 billion
Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions
What is Dr.Reddy's Laboratories' stock symbol?
Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."
How were Dr.Reddy's Laboratories' earnings last quarter?
Dr.Reddy's Laboratories Ltd (NYSE:RDY) issued its quarterly earnings results on Thursday, July, 26th. The company reported $0.40 EPS for the quarter. The company earned $543 million during the quarter, compared to the consensus estimate of $542.20 million. Dr.Reddy's Laboratories had a return on equity of 11.74% and a net margin of 9.41%. View Dr.Reddy's Laboratories' Earnings History.
When is Dr.Reddy's Laboratories' next earnings date?
What price target have analysts set for RDY?
1 brokerages have issued twelve-month price targets for Dr.Reddy's Laboratories' stock. Their predictions range from $30.51 to $30.51. On average, they anticipate Dr.Reddy's Laboratories' stock price to reach $30.51 in the next year. This suggests that the stock has a possible downside of 14.0%. View Analyst Price Targets for Dr.Reddy's Laboratories.
What is the consensus analysts' recommendation for Dr.Reddy's Laboratories?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Dr.Reddy's Laboratories.
Who are some of Dr.Reddy's Laboratories' key competitors?
Some companies that are related to Dr.Reddy's Laboratories include Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Bausch Health Companies (BHC) and Valeant Pharmaceuticals (VRX).
Who are Dr.Reddy's Laboratories' key executives?
Dr.Reddy's Laboratories' management team includes the folowing people:
- Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 58)
- Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 51)
- Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 57)
- Dr. Kandiraju Venkata Sita Ram Rao, Sr. VP, Bus. Head of PSAI Commercial Organization & Member of Management Council (Age 55)
- Dr. C. Cartikeya Reddy, Exec. VP, Head of Biologics & Member of Management Council (Age 48)
Who are Dr.Reddy's Laboratories' major shareholders?
Dr.Reddy's Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Commonwealth Bank of Australia (1.06%), BlackRock Inc. (0.94%), Advisors Asset Management Inc. (0.52%), Dimensional Fund Advisors LP (0.50%), Renaissance Technologies LLC (0.35%) and First Trust Advisors LP (0.25%).
Which institutional investors are selling Dr.Reddy's Laboratories stock?
RDY stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Montreal Can, Legal & General Group Plc, Zurcher Kantonalbank Zurich Cantonalbank, Greenleaf Trust, Migdal Insurance & Financial Holdings Ltd. and Commerzbank Aktiengesellschaft FI.
Which institutional investors are buying Dr.Reddy's Laboratories stock?
RDY stock was bought by a variety of institutional investors in the last quarter, including Advisors Asset Management Inc., Renaissance Technologies LLC, Millennium Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, NINE MASTS CAPITAL Ltd, Jane Street Group LLC and Acadian Asset Management LLC.
How do I buy shares of Dr.Reddy's Laboratories?
Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dr.Reddy's Laboratories' stock price today?
One share of RDY stock can currently be purchased for approximately $35.47.
How big of a company is Dr.Reddy's Laboratories?
Dr.Reddy's Laboratories has a market capitalization of $5.85 billion and generates $2.20 billion in revenue each year. The company earns $151 million in net income (profit) each year or $1.01 on an earnings per share basis. Dr.Reddy's Laboratories employs 23,524 workers across the globe.
What is Dr.Reddy's Laboratories' official website?
How can I contact Dr.Reddy's Laboratories?
Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]
MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
